Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Nov;47(11):1315-1318.
doi: 10.1007/s00134-021-06540-w. Epub 2021 Oct 7.

The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19?

Kate C Tatham  1   2 , Manu Shankar-Hari  3   4 , Yaseen M Arabi  5
Affiliations
Editorial

The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19?

Kate C Tatham et al. Intensive Care Med. 2021 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

KCT declares no competing interests. MS‐H is on the Editorial Board for ICM, an investigator on the REMAP-CAP trial, led the WHO REACT PMA on IL-6 antagonists. YA is on the Editorial Board for ICM and is an investigator on the REMAP-CAP trial.

References

    1. Marshall JC, Murthy S, Diaz J, Adhikari NK, Angus DC, Arabi YM, Baillie K, Bauer M, Berry S, Blackwood B, Bonten M, Bozza F, Brunkhorst F, Cheng A, Clarke M, Dat VQ, de Jong M, Denholm J, Derde L, Dunning J, Feng X, Fletcher T, Foster N, Fowler R, Gobat N, Gomersall C, Gordon A, Glueck T, Harhay M, Hodgson C, Horby P, Kim Y, Kojan R, Kumar B, Laffey J, Malvey D, Martin-Loeches I, McArthur C, McAuley D, McBride S, McGuinness S, Merson L, Morpeth S, Needham D, Netea M, Oh M-D, Phyu S, Piva S, Qiu R, Salisu-Kabara H, Shi L, Shimizu N, Sinclair J, Tong S, Turgeon A, Uyeki T, van de Veerdonk F, Webb S, Williamson P, Wolf T, Zhang J. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20:e192–e197. doi: 10.1016/S1473-3099(20)30483-7. - DOI - PMC - PubMed
    1. Osuchowski MF, Winkler MS, Skirecki T, Cajander S, Shankar-Hari M, Lachmann G, Monneret G, Venet F, Bauer M, Brunkhorst FM, Weis S, Garcia-Salido A, Kox M, Cavaillon JM, Uhle F, Weigand MA, Flohe SB, Wiersinga WJ, Almansa R, de la Fuente A, Martin-Loeches I, Meisel C, Spinetti T, Schefold JC, Cilloniz C, Torres A, Giamarellos-Bourboulis EJ, Ferrer R, Girardis M, Cossarizza A, Netea MG, van der Poll T, Bermejo-Martin JF, Rubio I. The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respir Med. 2021;9:622–642. doi: 10.1016/S2213-2600(21)00218-6. - DOI - PMC - PubMed
    1. Rosas IO, Diaz G, Gottlieb RL, Lobo SM, Robinson P, Hunter BD, Cavalcante AW, Overcash JS, Hanania NA, Skarbnik A, Garcia-Diaz J, Gordeev I, Carratal J, Gordon O, Graham E, Lewin-Koh N, Tsai L, Tuckwell K, Cao H, Brainard D, Olsson JK. Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial. Intensive Care Med. 2021 doi: 10.1007/s00134-021-06507-x. - DOI - PMC - PubMed
    1. Rochwerg B, Agarwal A, Siemieniuk RA, Agoritsas T, Lamontagne F, Askie L, Lytvyn L, Leo YS, Macdonald H, Zeng L, Amin W, Burhan E, Bausch FJ, Calfee CS, Cecconi M, Chanda D, Du B, Geduld H, Gee P, Harley N, Hashimi M, Hunt B, Kabra SK, Kanda S, Kawano-Dourado L, Kim YJ, Kissoon N, Kwizera A, Mahaka I, Manai H, Mino G, Nsutebu E, Preller J, Pshenichnaya N, Qadir N, Sabzwari S, Sarin R, Shankar-Hari M, Sharland M, Shen Y, Ranganathan SS, Souza JP, Stegemann M, De Sutter A, Ugarte S, Venkatapuram S, Dat VQ, Vuyiseka D, Wijewickrama A, Maguire B, Zeraatkar D, Bartoszko JJ, Ge L, Brignardello-Petersen R, Owen A, Guyatt G, Diaz J, Jacobs M, Vandvik PO. A living WHO guideline on drugs for covid-19. BMJ. 2020;370:m3379. doi: 10.1136/bmj.m3379. - DOI - PubMed
    1. Group WHOREAfC-TW. Shankar-Hari M, Vale CL, Godolphin PJ, Fisher D, Higgins JPT, Spiga F, Savovic J, Tierney J, Baron G, Benbenishty JS, Berry LR, Broman N, Cavalcanti AB, Colman R, De Buyser SL, Derde LPG, Domingo P, Omar SF, Fernandez-Cruz A, Feuth T, Garcia F, Garcia-Vicuna R, Gonzalez-Alvaro I, Gordon AC, Haynes R, Hermine O, Horby PW, Horick NK, Kumar K, Lambrecht BN, Landray MJ, Leal L, Lederer DJ, Lorenzi E, Mariette X, Merchante N, Misnan NA, Mohan SV, Nivens MC, Oksi J, Perez-Molina JA, Pizov R, Porcher R, Postma S, Rajasuriar R, Ramanan AV, Ravaud P, Reid PD, Rutgers A, Sancho-Lopez A, Seto TB, Sivapalasingam S, Soin AS, Staplin N, Stone JH, Strohbehn GW, Sunden-Cullberg J, Torre-Cisneros J, Tsai LW, van Hoogstraten H, van Meerten T, Veiga VC, Westerweel PE, Murthy S, Diaz JV, Marshall JC, Sterne JAC. Association between administration of IL-6 Antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA. 2021;326:499–518. doi: 10.1001/jama.2021.11330. - DOI - PMC - PubMed

Publication types

Substances